Skip to main content
BTC / USDT———ETH / USDT———SOL / USDT———BNB / USDT———XRP / USDT———DOGE / USDT———TON / USDT———AVAX / USDT———LINK / USDT———ADA / USDT———TRX / USDT———DOT / USDT———BTC / USDT———ETH / USDT———SOL / USDT———BNB / USDT———XRP / USDT———DOGE / USDT———TON / USDT———AVAX / USDT———LINK / USDT———ADA / USDT———TRX / USDT———DOT / USDT———
Visualize
Charts12 chart types: candlestick, Renko, P&F, deltaIndicators123 built-in, Barometer, no marketplaceDrawing tools82 tools: Fibonacci, Gann, Elliott, harmonicsPatterns59 candle, 19 chart and 9 harmonic patterns, auto-detected
Screen & automate
ScannerMulti-timeframe screening, 140 rulesStrategyBacktest with slippage and commissions, 40 presetsAuto-tradingWebhook, signal, DCA and grid bots
Build & practice
Any Script Converter6 languages, one clickPaper trading$10K virtual account, zero riskModules9 professional analysis modules
Open the terminal Multi-pane chart workspace. No install, free paper account.
How TW coins worksEarn TW coins for lessons, ideas, broker reviews and a daily habitLeaderboardWeekly traders ranking, resets every MondayLearn tradingLessons, quizzes and rewards TW coinsTW coinA loyalty score inside the product: earned for lessons, ideas and a daily habit. TW Coins are not money and cannot be bought, transferred or withdrawn.
Best BrokersCompare regulated forex, crypto, and stock brokers based on TW Score, regulatory status, and trader reviews.Brokers NewsCompany announcements and press releasesFind my brokerAnswer a few questions and see the brokersCompare brokersPick up to 4 brokers and compare themTrading calculatorsWork out pip value, position size and marginBroker regulatorsFinancial regulators grouped by grade and jurisdiction, and the brokers licensed by each
DocsConcepts and referenceIdeasLatest from the communityJournalLongreads, analytical articlesResearchMethod breakdowns on historical chartsProduct UpdatesNew features, releases and platform updatesWeb3 toolsLaunch and manage tokens without code
Pricing
Get started→
stocksJul 15, 2026, 10:27 AM

Johnson & Johnson Beats Q2 Estimates, Raises FY Guidance

Johnson & Johnson reported Q2 2026 adjusted EPS of $2.90, above the $2.85 estimate, and sales of $25.31B beating $25.04B. The company raised its full-year sales and adjusted EPS guidance.

JNJ

Johnson & Johnson (JNJ) reported Q2 2026 earnings that surpassed analyst expectations. Adjusted EPS came in at $2.90 versus the consensus estimate of $2.85. Revenue reached $25.31 billion, ahead of the $25.04 billion forecast.

Medtech sales totaled $8.93 billion, slightly below the estimated $8.99 billion. Medicine revenue was $16.38 billion, exceeding the $16.12 billion estimate.

The company raised its full-year 2026 guidance. FY sales are now seen at $100.8 billion to $101.4 billion, up from the prior range of $100.3 billion to $101.3 billion. FY adjusted EPS guidance was lifted to $11.60-$11.75 from $11.45-$11.65.

Source: First Squawk